AQ00 P line

AQ00 P line is a preclinical-stage inhaled corticosteroid formulation developed by Aquoralon Pharmaceuticals (also known as Aquilon Pharma) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The "P line" (Proprietary line) utilizes a proprietary cyclodextrin-based drug delivery platform designed to enhance the solubility, stability, and lung deposition of corticosteroids. By optimizing the delivery of the active anti-inflammatory agent via a dry powder inhaler (DPI), the program aims to improve therapeutic outcomes and potentially reduce systemic side effects compared to conventional inhaled therapies. The specific corticosteroid molecule within this proprietary line has not been publicly disclosed, but it is part of a broader portfolio of cyclodextrin-enhanced inhaled therapies.